⌘K
Loading ticker…
As of 2026-08-25, MIRA Pharmaceuticals, Inc. Common Stock (MIRA) has a 3-month relative strength percentile of 20 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 38. The current market Stance is 52.9 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 9.5%, relative volume 0.35×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
MIRA is in a stage 4 downtrend, week 9. Extended from base. VCP detected: inconclusive. Distance from 50d / 200d: -9.7% / -31.8%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
MIRA is held by 2 ETFs as of Mar 2026. Top owner: VXF at 0.00% weight, $382K notional.
Held by 2 ETFs · $742K across latest filings · largest weight 0.00% (VXF).
Top 2 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $382K | — |
| VTIVanguard Total Stock Market ETF | 0.00% | $361K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | MIRA Jan avg: -7.70% median: -10.48% win: 33% σ: 11.82% n: 3 2023-08-04 → 2026-07-31 | MIRA Feb avg: -2.44% median: 2.42% win: 67% σ: 12.52% n: 3 2023-08-04 → 2026-07-31 | MIRA Mar avg: -2.77% median: -2.00% win: 33% σ: 12.62% n: 3 2023-08-04 → 2026-07-31 | MIRA Apr avg: -2.08% median: -1.87% win: 33% σ: 20.55% n: 3 2023-08-04 → 2026-07-31 | MIRA May avg: 4.53% median: 0.95% win: 67% σ: 10.52% n: 3 2023-08-04 → 2026-07-31 | MIRA Jun avg: -14.41% median: -10.71% win: 0% σ: 6.70% n: 3 2023-08-04 → 2026-07-31 | MIRA Jul avg: 83.24% median: 36.36% win: 67% σ: 129.52% n: 3 2023-08-04 → 2026-07-31 | MIRA Aug avg: -13.51% median: -15.45% win: 0% σ: 4.75% n: 3 2023-08-04 → 2026-07-31 (current) | MIRA Sep avg: -19.75% median: -25.88% win: 0% σ: 16.82% n: 3 2023-08-04 → 2026-07-31 | MIRA Oct avg: 10.99% median: 22.79% win: 67% σ: 64.19% n: 3 2023-08-04 → 2026-07-31 | MIRA Nov avg: 10.17% median: -11.38% win: 33% σ: 64.79% n: 3 2023-08-04 → 2026-07-31 | MIRA Dec avg: -26.67% median: -11.63% win: 33% σ: 38.50% n: 3 2023-08-04 → 2026-07-31 |